Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. (6th April 2023)

• Record Type: Journal Article
• Authors: Macklin, Grace R.; Peak, Corey; Eisenhawer, Martin; Kurji, Feyrouz; Mach, Ondrej; Konz, John; Gast, Chris; Bachtiar, Novilia Sjafri; Bandyopadhyay, Ananda S.; Zipursky, Simona
• Is Part Of: Vaccine. Volume 41(2023)Supplement 1
• Page Start: A122
• Page End: A127
• Publication Date: 2023-04-06
• Subjects: Poliovirus -- Vaccine -- Emergency use listing -- Novel oral poliovirus vaccine -- Public health emergency of international concern; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.02.050
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response – novel oral polio vaccine type 2 (nOPV2). The World Health Organization's (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for nOPV2 on 13 November 2020. The WHO's EUL procedure was created to assess and list unlicensed vaccines, therapeutics and diagnostics to enable their use in response to a Public Health Emergency of International Concern (PHEIC). nOPV2 was the first vaccine to receive an EUL, paving the way for other emergency vaccines. In this report, we summarise the pathway for nOPV2 roll-out under EUL.